Chat with us, powered by LiveChat

Animal Study has Positive Results for Inhaled PIV5 Vaccine

Print Friendly, PDF & Email

EDITOR NOTE: Believe it or not, animal researchers studying the effects of the virus central to the current pandemic claimed to have developed an “inhalable” vaccine called PIV5. No shots needed, just a whiff. Not only did it protect mice from infection, it also blocked transmission. Incredibly, this platform--smellable vaccines--has been in development for the last 20 years. So, might this be an innovative step toward accelerating the vaccine rollout? Might it only work for mice or other small animals, or might it be effective for the biggest and most “intelligent” apes on the planet (hopefully you’ve figured out what that might be)? Or is it another pipe dream--more specifically, a “nasal nostrum”--that ultimately just stinks? 

One dose of an inhaled COVID-19 vaccine showed success in animal studies, researchers say, possibly opening the door for another option that’s easier to administer than the traditional needle shots. The vaccine, dubbed PIV5, was developed using a platform previously used for influenza vaccines and targets mucosal cells that line the nasal passages and airways. 

In a recent study involving mice, researchers from the University of Iowa and University of Georgia found it fully protected the animals from lethal COVID-19 infection and blocked animal-to-animal transmission of the virus in ferrets. Results were published July 2 in the journal Science Advances. 

"We have been developing this vaccine platform for more than 20 years, and we began working on new vaccine formulations to combat COVID-19 during the early days of the pandemic," said Biao He, a professor in the University of Georgia’s Department of Infectious Diseases in the College of Veterinary Medicine and co-leader of the study. "Our preclinical data show that this vaccine not only protects against infection but also significantly reduces the chances of transmission." 

The vaccine was stable for up to three months when stored at normal refrigerator temperatures, the researchers said. 

"The currently available vaccines against COVID-19 are very successful, but the majority of the world’s population is still unvaccinated and there is a critical need for more vaccines that are easy to use and effective at stopping disease and transmission," said Dr. Paul McCray, professor of pediatrics-pulmonary medicine as well as microbiology and immunology at the UI Carver College of Medicine, a co-leader of the study. "If this new COVID-19 vaccine proves effective in people, it may help block SARS-CoV-2 transmission and help control the COVID-19 pandemic." 

Several nasal vaccines are in the works and have reached clinical trials, but none have been submitted for authorization yet. 

Original post from Fox News

Bank Failure Scenario Kit - sm2



  • This field is for validation purposes and should be left unchanged.

All articles are provided as a third party analysis and do not necessarily reflect the explicit views of GSI Exchange and should not be construed as financial advice.

Precious Metals and Currency Data Powered by nFusion Solutions